Myogenic tissue nanotransfection improves muscle torque recovery following volumetric muscle loss.

Andrew ClarkSubhadip GhatakPoornachander Reddy GudaMohamed S El Masry Yi Xuan Amy Y SatoTeresita BellidoChandan K Sen

Published in: NPJ Regenerative medicine (2022)

This work rests on our non-viral tissue nanotransfection (TNT) platform to deliver MyoD (TNT MyoD ) to injured tissue in vivo. TNT MyoD was performed on skin and successfully induced expression of myogenic factors. TNT MyoD was then used as a therapy 7 days following volumetric muscle loss (VML) of rat tibialis anterior and rescued muscle function. TNT MyoD is promising as VML intervention.

Keyphrases

skeletal muscle
randomized controlled trial
poor prognosis
sars cov
oxidative stress
diabetic rats
mesenchymal stem cells
cell therapy
replacement therapy